{"id":"NCT03493542","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)","officialTitle":"A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-31","primaryCompletion":"2023-10-30","completion":"2023-10-30","firstPosted":"2018-04-10","resultsPosted":"2020-05-04","lastUpdate":"2024-12-31"},"enrollment":766,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ"],"interventions":[{"type":"BIOLOGICAL","name":"V501","otherNames":["(Gardasil®) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine","qHPV"]}],"arms":[{"label":"Chinese Girls Aged 9 to 19 Years","type":"EXPERIMENTAL"},{"label":"Chinese Young Women Aged 20 to 26 Years","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus \\[qHPV\\] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years. The primary hypothesis of the study states that at 1 month postdose 3, a 3-dose regimen of V501 induces non-inferior geometric mean titers (GMTs) for serum anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18 in girls aged 9-19 years compared to young women aged 20-26 years.","primaryOutcome":{"measure":"Base Stage: Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA)","timeFrame":"Month 7 (1 month postdose 3)","effectByArm":[{"arm":"Chinese Girls Aged 9 to 19 Years","deltaMin":975.2,"sd":null},{"arm":"Base Study: Chinese Young Women Aged 20 to 26 Years","deltaMin":686.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":20},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["33239228"],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":383},"commonTop":["Injection site pain","Pyrexia","Fatigue","Cough","Headache"]}}